UBS analyst Danielle Antalffy raised the firm’s price target on RxSight (RXST) to $9 from $8 and keeps a Neutral rating on the shares. The lower 2026 outlook should limit downside risk, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight reports Q4 EPS (3c), consensus (20c)
- RxSight sees FY26 revenue $120M-$135M, consensus $135.34M
- RXST Upcoming Earnings Report: What to Expect?
- Spotify upgraded, Pinterest downgraded: Wall Street’s top analyst calls
- RxSight: Unique Adjustable IOL Technology Offset by Slowing Momentum and Execution Risks Supports Hold Rating